NEW YORK (GenomeWeb) – Interpace Diagnostics today announced that an independent Blue Cross Blue Shield plan has begun covering the firm's ThyGenX Thyroid Oncogene Panel and ThyraMIR Thyroid miRNA Classifier, molecular tests for indeterminate thyroid nodules. 

Interpace, a subsidiary of PDI, did not identify the BCBS plan but said that it insures 3.3 million lives and added that it is the first commercial plan to cover ThyraMIR, a microRNA gene expression classifier launched earlier this year for identifying indeterminate benign and malignant thyroid nodules. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.